YERVOY (E.R. Squibb & Sons, L.L.C.)
Welcome to the PulseAid listing for the YERVOY drug offered from E.R. Squibb & Sons, L.L.C.. This CTLA-4-directed Blocking Antibody [EPC],CTLA-4-directed Antibody Interactions [MoA],Increased T Lymphocyte Activation [PE] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | E.R. Squibb & Sons, L.L.C. |
| NON-PROPRIETARY NAME: | ipilimumab |
| SUBSTANCE NAME: | IPILIMUMAB |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | CTLA-4-directed Blocking Antibody [EPC],CTLA-4-directed Antibody Interactions [MoA],Increased T Lymphocyte Activation [PE] |
| ROUTE: | INTRAVENOUS |
| DOSAGE FORM: | INJECTION |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 2011-03-25 |
| END MARKETING DATE: | 0000-00-00 |
YERVOY HUMAN PRESCRIPTION DRUG Details:
| Item Description | YERVOY from E.R. Squibb & Sons, L.L.C. |
| LABELER NAME: | E.R. Squibb & Sons, L.L.C. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 5(mg/mL) |
| START MARKETING DATE: | 2011-03-25 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0003-2327_f5b93ca8-1cae-4c0e-9363-cd09a1d83ac1 |
| PRODUCT NDC: | 0003-2327 |
| APPLICATION NUMBER: | BLA125377 |
Other IPILIMUMAB Pharmaceutical Manufacturers / Labelers:
